Antiviral Effect of Propylene Glycol against Envelope Viruses in Spray and Volatilized Forms

Viruses. 2023 Jun 23;15(7):1421. doi: 10.3390/v15071421.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly contagious and continues to spread worldwide. To avoid the spread of infection, it is important to control its transmission routes. However, as methods to prevent airborne infections are lacking, people are forced to take measures such as keeping distance from others or wearing masks. Here, we evaluate the antiviral activity of propylene glycol (PG), which is safe, odorless, and volatile. PG showed pronounced antiviral activity against the influenza virus (IAV) at concentrations above 55% in the liquid phase. Given its IAV inactivation mechanism, which involves increasing the fluidity of the viral membrane, PG is expected to have a broad effect on enveloped viruses. PG showed antiviral activity against SARS-CoV-2. We also developed a system to evaluate the antiviral effect of PG in spray and volatilized forms. PG was found to be effective against aerosol IAV in both forms; the effective PG concentration against IAV in the vapor phase was 87 ppmv (0.27 mg/L). These results demonstrate that PG is an effective means for viral inactivation in various situations for infection control. This technology is expected to control the spread of current and future infectious diseases capable of causing outbreaks and pandemics.

Keywords: COVID-19; aerosol; antiviral; infectious diseases; influenza virus; propylene glycol.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents* / pharmacology
  • Antiviral Agents* / therapeutic use
  • COVID-19*
  • Humans
  • Propylene Glycols
  • Respiratory Aerosols and Droplets
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Propylene Glycols

Grants and funding

This study was fully funded by the Kao Corporation (http://www.kao.com/, accessed on 8 May 2023), and all authors were permanent employees of the Kao Corporation. The Kao Corporation provided support in the form of salaries for all authors but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.